KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) FCF Margin (2016 - 2025)

Historic FCF Margin for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to 25.06%.

  • Alnylam Pharmaceuticals' FCF Margin rose 171700.0% to 25.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.37%, marking a year-over-year increase of 76000.0%. This contributed to the annual value of 1.89% for FY2024, which is 41900.0% down from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' FCF Margin stood at 25.06%, which was up 171700.0% from 18.02% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year FCF Margin high stood at 45.61% for Q3 2023, and its period low was 424.28% during Q1 2025.
  • For the 5-year period, Alnylam Pharmaceuticals' FCF Margin averaged around 54.62%, with its median value being 45.85% (2022).
  • In the last 5 years, Alnylam Pharmaceuticals' FCF Margin soared by 1247900bps in 2021 and then crashed by -4051700bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' FCF Margin stood at 66.54% in 2021, then skyrocketed by 31bps to 45.85% in 2022, then surged by 78bps to 10.26% in 2023, then plummeted by -71bps to 17.49% in 2024, then soared by 243bps to 25.06% in 2025.
  • Its last three reported values are 25.06% in Q3 2025, 18.02% for Q2 2025, and 424.28% during Q1 2025.